$ABEO

Vazzano Joseph Walter sold $265K of ABEO

Vazzano Joseph Walter (Chief Financial Officer) sold 49,338 shares of ABEONA THERAPEUTICS INC. (ABEO) at an average of $5.38 ($5.30–$5.43, $0.27M total) across 3 trades over 2026-06-08 to 2026-06-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Vazzano Joseph Walter
Published Jun 10, 2026, 12:32 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 10, 2026, 1:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ABEO
Neutral
medium confidence
Mentioned
$ABEO
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABEONeutralLow
01

Why it matters

The disclosure provides a concrete, time-stamped insider selling event (open-market sale) but does not include any new company fundamentals or guidance changes.

02

Market read

Useful for monitoring insider behavior and potential sentiment, but not a standalone fundamental driver.

03

What to watch

Traders should check whether ABEO has concurrent news (financing, trial updates, guidance) since this filing alone doesn’t provide that context.

Relevance 3/10Novelty 6/10Timing: filed 2026-06-09T20:32:55-04:00 (covers sales 2026-06-08 to 2026-06-09)

Background

The article is an SEC Form 4 insider transaction disclosure for ABEONA THERAPEUTICS (ABEO).

Company-level read

Ticker impact

$ABEONeutralMedium confidence
Context

ABEO CFO Vazzano sold $265,242 of ABEO shares via an open-market sale under a pre-arranged 10b5-1 plan (49,338 shares).

Expected impact

Low near-term impact; any effect is likely sentiment-driven and short-lived unless paired with other news.

Evidence & confidence

Form 4 shows an officer selling under a 10b5-1 plan, which reduces the signal of new negative information; the article contains no operational/financial updates.

Market effects

Minimal; single-company insider transaction without sector-wide implications.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • ABEO

    Abeona Therapeutics Inc.; subject of the Form 4 insider sale by its CFO.

  • Vazzano Joseph Walter

    Chief Financial Officer who sold ABEO shares.

  • 10b5-1 plan

    Pre-arranged plan cited as the basis for the scheduled insider sales.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ABEOMed

Abeona Therapeutics Swings To Q2 Net Loss; Shares Plunge

Abeona Therapeutics (ABEO) reported Q2 2026 results showing a swing to a net loss of $20.19M, or $0.35/share, versus net income of $108.83M, or $1.71/share, a year earlier largely due to a $152.37M priority review voucher gain. Q2 revenue rose to $11.38M from $0.40M. Cash totaled $146.8M as of June 30. ZEVASKYN treated 5 patients in Q2.

$ABEOMedAI 8/10

Why is Abeona Therapeutics stock slumping today?

Abeona Therapeutics (ABEO) shares fell 15.8% pre-open after it reported Q2 2026 results. The company posted a loss of 35 cents per share versus a year-earlier profit of $1.71, and revenue of $11.4M versus an estimated $12.2M. Revenue recognition for ZEVASKYN was limited by a manufacturing batch yield shortfall.

$ABEOMed

ABEONA THERAPEUTICS INC. (ABEO): Results of Operations and Financial Condition

ABEONA THERAPEUTICS INC. (ABEO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Abeona Therapeutics ® Reports Second Quarter 2026 Results and Provides Business Update - Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million – - Five patients treated with ZEVASKYN in Q2 2026 and three treatments in Q3 2026 to-date; since lau

$ABEOMedAI 8/10

A new CMS payment could help Medicare patients access ZEVASKYN

Abeona Therapeutics (Nasdaq: ABEO) said CMS granted ZEVASKYN (prademagene zamikeracel) NTAP status under the FY2027 Hospital Inpatient Prospective Payment System rule. Abeona said NTAP adds supplemental Medicare reimbursement for technologies showing substantial clinical improvement. The company also reiterated ZEVASKYN’s safety risks, including potential cancer risk and serious allergic reactions.